Rapid development of infusion-related severe hypotension during rituximab therapy

Annals of Pharmacotherapy

Volumn 45, Issue 5, 2011, Pages

  Vo, Kevin H ^a   Waddell, James Aubrey ^a   Suda, Katie J ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Adverse drug reaction; Hypotension; Infusion related toxicity; Rituximab

Indexed keywords

AMLODIPINE; ATORVASTATIN; CLOPIDOGREL; DEXAMETHASONE; DIPHENHYDRAMINE; IRBESARTAN; METHYLPREDNISOLONE; METOPROLOL; MULTIVITAMIN; ONDANSETRON; PARACETAMOL; PETHIDINE; RITUXIMAB;

AGED; ANEMIA; ARTICLE; BREATHING RATE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARDIOMEGALY; CASE REPORT; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; HUMAN; HYPOTENSION; LUNG CONGESTION; LYMPHOCYTOSIS; MALE; OXYGEN SATURATION; PRIORITY JOURNAL; PROVOCATION TEST; PULSE RATE; RIGOR; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; HUMANS; HYPOTENSION; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE;

EID: 79957559459     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P733     Document Type: Article

References (11)

1. Dillman RO, Hendrix CS. Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther 2003;1:38-48.
2. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003;63:803-43.
3. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70:1445-76.
4. Lim LC, Koh LF, Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol 1999;17:1962-3.
5. Cvetkoviç RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006;66:791-820.
6. Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs 2010;14:10-21.
7. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008;13:725-32.
8. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823-37.
9. Product information. Rituxan (rituximab). South San Francisco, CA: Genentech, Inc, January 2011.
10. Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs 2007;11:37-42.
11. Naranjo CA, Busto M, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.